The inhibition of RAS with angiotensin II type 1 receptor (AT-1R) blockers could prevent the initiation and deterioration of podocyte injury, providing new insight into the treatment of renal impairment post-MI with resultant left ventricular dysfunction [3,4]. Here, AGTR1 is linked to myocardial infarction.